|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Thursday, October 05, 2006
Elan Extends Tysabri's Reach to Canada [more]
...To put this in perspective, Canada has possibly the highest rate of MS in the whole world. An estimated 55,000 to 75,000 Canadians suffer from the disease -- that's nearly one-fifth the estimated number of patients in the United States. The fortunes of Elan will rise and fall with the prospects of Tysabri. When the drug was taken off the market early last year, many investors pegged the company for bankruptcy because of its high debt load. Now that the drug has been approved for sale again in the U.S. and also for marketing in the EU, Elan has a chance to start making enough money to stem the company's losses and hopefully begin paring down some of the nearly $2 billion in debt that will be due in varying amounts in 2008 and 2011..... |